NICE guidance (NG28) recommends considering dose reductions of insulin or sulfonylureas when initiating a GLP-1 receptor agonist to mitigate this risk
Inspired by Babu and Krishnan [1] review on PDTs effectiveness in oral cancer treatment, we explored LXD191, a novel therapeutic agent combining lipophilic diarylacetylene and hydroxamic acid (HA), for its dual-action mechanism of PDT and histone deacetylase (HDAC) inhibition [2,3,4]
Arch Histol Cytol
Guidelines for pharmacologic therapy for weight regain after bariatric surgery with GLP-1 receptor agonists have evolved as these medications demonstrate promising efficacy in this population
From the moment you walk in to the final mirror check, every detail is designed to wow you
* Correspondence: Evgeny Ruchko, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
